FEBUCO-80 TAB

Febuco-80 

 Product: Febuco-80

Dosage form: Film-coated tablet
Strength: 80 mg
Active ingredient: Febuxostat

1. Active pharmaceutical ingredient (API)

Febuxostat — 80 mg per tablet

Febuxostat is the pharmacologically active component of Febuco-80. It belongs to the xanthine oxidase inhibitor class.

Its main action is to inhibit the enzyme xanthine oxidase, which is involved in the conversion of:

Hypoxanthine → Xanthine → Uric acid

By reducing xanthine oxidase activity, febuxostat decreases the production of uric acid, thereby lowering serum uric-acid concentrations.

The 80 mg designation means that each tablet contains 80 mg of febuxostat.

2. Excipients

The package states:

“Excipients — q.s.”

Here, q.s. = quantum sufficiens, meaning quantity sufficient to manufacture the tablet to the required specifications.

Excipients are inactive ingredients and may perform functions such as:

• Giving the tablet its required size and shape

• Providing adequate mechanical strength

• Helping the tablet disintegrate and release the active ingredient

• Improving manufacturing and compression

• Maintaining stability

• Providing the film coating and its physical properties

Important: The supplied blister/pack does not list the individual excipients or their quantities, so their specific names cannot be reliably provided from this image.

3. Titanium Dioxide IP

The pack specifically states:

“Colour: Titanium Dioxide IP”

Titanium dioxide is used as a white pigment/opacifying agent, particularly in pharmaceutical tablet coatings.

Its purposes can include:

• Giving the tablet coating a white, uniform appearance

• Improving opacity

• Helping provide a consistent visual appearance

• Providing some protection of the tablet from light exposure

IP indicates that the ingredient conforms to the applicable Indian Pharmacopoeia standard.

4. Composition in pharmaceutical format

A detailed way of writing the composition from the pack is:

Each film-coated tablet contains:
Febuxostat IP/BP — 80 mg
Excipients — q.s.
Colour — Titanium Dioxide IP
Dosage — As directed by the physician.

The image itself clearly establishes Febuxostat 80 mg, excipients q.s., and Titanium Dioxide IP. It does not provide enough information to identify the complete excipient formula.

5. What “80 mg” means

The 80 mg refers to febuxostat, not to the total weight of the tablet.

The finished tablet will weigh more than 80 mg because it also contains the inactive excipients and coating materials.

For example:

Total tablet weight = Febuxostat 80 mg + excipients + coating components

The exact total tablet weight is not stated on the supplied packaging.

6. Therapeutic purpose of the composition

The composition is designed primarily to lower elevated uric-acid levels.

Febuxostat inhibits xanthine oxidase → reduces uric-acid synthesis → lowers circulating uric acid.

It is therefore used in the management of hyperuricemia associated with gout, according to the prescribing indication.

Note: Febuco-80 is a prescription medicine. The dose and duration should be determined by a physician, particularly because febuxostat treatment has important considerations involving cardiovascular history, liver function, kidney function, and other medicines.